(Q40401339)

20 September 2017

title

Quality of life and costs for different treatment strategies for rheumatoid arthritis (English)

1 reference

20 September 2017

0 references

Paco M J Welsing

1

1 reference

20 September 2017

Wietske Kievit

series ordinal

2

1 reference

20 September 2017

Roland F J M Laan

series ordinal

3

1 reference

20 September 2017

Johan L Severens

series ordinal

4

1 reference

20 September 2017

publication date

1 August 2005

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

20 September 2017

published in

1 reference

20 September 2017

volume

5

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

395-410

1 reference

Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Risk factors for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Classification criteria for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Rheumatoid arthritis. Designing and implementing a treatment plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Measuring health status in arthritis. The arthritis impact measurement scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

EuroQol--a new facility for the measurement of health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

An empirical comparison of four generic health status measures. The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Measurement of the quality of life in rheumatic disorders using the EuroQol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The Health Utilities Index (HUI): concepts, measurement properties and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Cost of illness studies in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Economic burden of rheumatoid arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Rheumatoid arthritis: direct and indirect costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Modelling in economic evaluation: an unavoidable fact of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Leflunomide in rheumatoid arthritis: recommendations through a process of consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Combination therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Funding medicines for people with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Patient preferences for treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Determinants of direct costs in Dutch rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

AIMS2. The Content and Properties of a Revised and Expanded Arthritis Impact Measurement Scales Health Status Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Primer on Medical Decision Analysis: Part 5—Working with Markov Processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

Patient-reported outcomes and their role in the assessment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.4.395

21 January 2018

Identifiers

DOI

10.1586/14737167.5.4.395

1 reference

20 September 2017

1 reference